Diversify Advisory Services LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,889 shares of the company's stock, valued at approximately $858,000.
A number of other institutional investors also recently modified their holdings of the stock. Quadrant Capital Group LLC lifted its position in shares of Penumbra by 6.6% during the 4th quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock valued at $150,000 after acquiring an additional 39 shares during the period. Baker Avenue Asset Management LP raised its holdings in Penumbra by 1.6% during the fourth quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock worth $791,000 after buying an additional 53 shares during the last quarter. Fifth Third Bancorp raised its holdings in Penumbra by 16.4% during the first quarter. Fifth Third Bancorp now owns 404 shares of the company's stock worth $108,000 after buying an additional 57 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Penumbra by 3.7% during the fourth quarter. Corient Private Wealth LLC now owns 1,695 shares of the company's stock worth $403,000 after buying an additional 61 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in shares of Penumbra by 404.8% in the first quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock valued at $28,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.
Penumbra Price Performance
PEN stock traded up $0.37 during midday trading on Wednesday, reaching $232.25. The company had a trading volume of 91,889 shares, compared to its average volume of 455,921. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.30 and a quick ratio of 3.68. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The company has a market capitalization of $9.00 billion, a P/E ratio of 219.52, a P/E/G ratio of 2.04 and a beta of 0.47. The firm has a 50-day moving average price of $258.27 and a 200-day moving average price of $268.38.
Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. Penumbra had a net margin of 3.41% and a return on equity of 11.14%. The business had revenue of $324.14 million during the quarter, compared to analysts' expectations of $315.72 million. During the same quarter in the previous year, the company earned $0.41 EPS. The business's quarterly revenue was up 16.3% compared to the same quarter last year. On average, research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.
Insider Transactions at Penumbra
In other news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $252.70, for a total value of $151,620.00. Following the completion of the sale, the executive vice president directly owned 66,057 shares in the company, valued at approximately $16,692,603.90. The trade was a 0.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Adam Elsesser sold 15,985 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $243.75, for a total transaction of $3,896,343.75. Following the sale, the chief executive officer owned 134,432 shares of the company's stock, valued at $32,767,800. This represents a 10.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,185 shares of company stock worth $31,073,762. 5.00% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several analysts have recently commented on PEN shares. Robert W. Baird increased their target price on shares of Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Wells Fargo & Company lifted their target price on shares of Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Truist Financial lifted their target price on shares of Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. UBS Group reiterated a "buy" rating and issued a $330.00 target price (up previously from $320.00) on shares of Penumbra in a research note on Thursday, April 24th. Finally, BTIG Research reiterated a "buy" rating on shares of Penumbra in a research note on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Penumbra presently has a consensus rating of "Buy" and a consensus price target of $305.07.
Check Out Our Latest Research Report on Penumbra
About Penumbra
(
Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Read More

Before you consider Penumbra, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.
While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.